MSDC-0160, a novel clinical-stage mitochondrial pyruvate carrier inhibitor, suppresses osteoclast differentiation and alleviates type 2 diabetes-related bone loss
Abstract Objective Diabetic osteoporosis is a secondary complication of diabetes mellitus, characterized by reduced bone mass, increased bone fragility, and impaired fracture healing. However, the mechanisms underlying diabetic bone loss remain to be fully elucidated. More importantly, there is an u...
Sparad:
| Huvudupphov: | , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
BMC
2026-01-01
|
| Serie: | Journal of Translational Medicine |
| Ämnen: | |
| Länkar: | https://doi.org/10.1186/s12967-026-07699-w |
| Taggar: |
Inga taggar, Lägg till första taggen!
|